Venture • Life Science

HBM Partners Invests In Hookipa

On December 11, 2017, private equity firm HBM Partners invested in life science company Hookipa

Investment Context
  • This is HBM Partners’ 14th transaction in the Life Science sector.
  • This is HBM Partners’ 13th transaction in the United States.
  • This is HBM Partners’ 1st transaction in New York.
Investment Fate
  • Hookipa went public in 2019.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date December 11, 2017
Target Hookipa
Sector Life Science
Investor(s) HBM Partners
Deal Type Venture

Target Company

Hookipa

New York, New York, United States
Hookipa is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. Hookipa was founded in 2011 and is based in New York, New York.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

HBM Partners

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.


Deal Context for Investor #
Overall 18 of 66
Sector: Life Science 14 of 56
Type: Venture 12 of 52
State: New York 1 of 1
Country: United States 13 of 44
Year: 2017 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-02 Allena Pharmaceuticals

Newton, Massachusetts, United States

Allena Pharmaceuticals is a clinical biopharma company developing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena Pharmaceuticals was founded in 2011 and is based in Newton, Massachussetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-22 Sublimity Therapeutics

Dublin, Ireland

Sublimity Therapeutics is a specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases. Sublimity Therapeutics was founded in 2003 and is based in Dublin, Ireland.

Buy -